Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 May 16:16:104.
doi: 10.1186/s12877-016-0281-7.

Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review

Qingwei Ruan  1 , Grazia D'Onofrio  2 , Daniele Sancarlo  3 , Zhijun Bao  1 , Antonio Greco  3 , Zhuowei Yu  4   5
Affiliations

Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review

Qingwei Ruan et al. BMC Geriatr. .

Abstract

Background: Neuroimaging-biomarkers of Mild Cognitive Impairment (MCI) allow an early diagnosis in preclinical stages of Alzheimer's disease (AD). The goal in this paper was to review of biomarkers for Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD), with emphasis on neuroimaging biomarkers.

Methods: A systematic review was conducted from existing literature that draws on markers and evidence for new measurement techniques of neuroimaging in AD, MCI and non-demented subjects. Selection criteria included: 1) age ≥ 60 years; 2) diagnosis of AD according to NIAAA criteria, 3) diagnosis of MCI according to NIAAA criteria with a confirmed progression to AD assessed by clinical follow-up, and 4) acceptable clinical measures of cognitive impairment, disability, quality of life, and global clinical assessments.

Results: Seventy-two articles were included in the review. With the development of new radioligands of neuroimaging, today it is possible to measure different aspects of AD neuropathology, early diagnosis of MCI and AD become probable from preclinical stage of AD to AD dementia and non-AD dementia.

Conclusions: The panel of noninvasive neuroimaging-biomarkers reviewed provides a set methods to measure brain structural and functional pathophysiological changes in vivo, which are closely associated with preclinical AD, MCI and non-AD dementia. The dynamic measures of these imaging biomarkers are used to predict the disease progression in the early stages and improve the assessment of therapeutic efficacy in these diseases in future clinical trials.

Keywords: Alzheimer’s disease; Magnetic resonance imaging; Mild cognitive impairment; Positron emission tomography.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow diagram outlining the selection procedure to identify articles which were included in the systematic review of neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer’s disease
See this image and copyright information in PMC

References

    1. Braak H, Del Tredici K. Where, when, and in what form does sporadic Alzheimer disease begin? Curr Opin Neurol. 2012;25(6):708–14. doi: 10.1097/WCO.0b013e32835a3432. - DOI - PubMed
    1. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9. doi: 10.1016/j.jalz.2011.03.005. - DOI - PMC - PubMed
    1. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–8. doi: 10.1001/archneur.56.3.303. - DOI - PubMed
    1. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging—Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270–9. doi: 10.1016/j.jalz.2011.03.008. - DOI - PMC - PubMed
    1. Jansen WJ, Ossenkoppele MR, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia A meta-analysis. JAMA. 2015;313(19):1924–38. doi: 10.1001/jama.2015.4668. - DOI - PMC - PubMed

Publication types

LinkOut - more resources